Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Ehlenberger

Emergency Medicine Kenner, LA Medical Doctor

NPI 1518073576 CMS profile 340629

2401 Veterans Memorial Blvd Ste 16, Accurate Clinic, Kenner, LA 70062

Open in the dashboard

General payments

$9,665

434 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Ehlenberger of Kenner, LA is reported in the CMS Open Payments database as having received $9,665 across 434 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,510 84
2024 General $1,625 95
2023 General $928 70
2022 General $908 42
2021 General $970 40
2020 General $356 34
2019 General $3,368 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Ehlenberger
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Eric Ehlenberger were reported at $1,510. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Eric Ehlenberger Emergency Medicine median Middle half National median
2019 $3,368 $51 $18–$128 $163
2020 $356 $29 $16–$99 $114
2021 $970 $40 $18–$124 $132
2022 $908 $49 $20–$134 $149
2023 $928 $51 $22–$142 $160
2024 $1,625 $52 $22–$150 $164
2025 $1,510 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biodelivery Sciences International, Inc. $2,659 18 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $869 76 payments
  3. AbbVie, Inc. $711 37 payments
  4. Scilex Pharmaceuticals Inc. $638 46 payments
  5. Collegium Pharmaceutical, Inc. $626 46 payments
  6. Pfizer Inc. $577 30 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $488 27 payments
  8. Biohaven Pharmaceuticals, Inc. $464 20 payments
  9. Valinor Pharma, LLC $437 35 payments
  10. Forte Bio-Pharma LLC $382 6 payments
  11. Other $1,813 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,485 432 payments
  2. Honoraria $2,000 1 payment
  3. Travel and Lodging $180 1 payment
Products named General payments · program years 2019–2025
  1. BELBUCA Addiction Therapy $2,561 4 payments
  2. NURTEC ODT $952 47 payments
  3. ZTLido $597 44 payments
  4. RELISTOR Gastroenterology $570 46 payments
  5. UBRELVY $556 34 payments
  6. QULIPTA $467 24 payments
  7. MOVANTIK $411 34 payments
  8. BELBUCA Opioid Analgesic $331 21 payments
  9. RELISTOR Gastroenterology $299 30 payments
  10. ZAVZPRET $270 14 payments
  11. Other $4,129 232 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

5,991

Median for Emergency Medicine: 88

Drug cost

$1,553,381

Median for Emergency Medicine: $590

Branded share of claims

39.1%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 638 $466,063
Belbuca Buprenorphine Hcl Brand 159 $147,679
Ztlido Lidocaine Brand 143 $144,998
Lidocan Iii Lidocaine Brand 53 $125,870
Levorphanol Tartrate Generic 49 $87,137
Relistor Methylnaltrexone Bromide Brand 35 $80,404
Xtampza Er Oxycodone Myristate Brand 71 $65,746
Lidocaine Generic 194 $41,847
Nurtec Odt Rimegepant Sulfate Brand 19 $38,433
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 761 $36,952

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $274
$274 35 —
MOVANTIK
  • Valinor Pharma, LLC $256
$256 48 —
ZTLido
  • Scilex Pharmaceuticals Inc. $196
$196 143 —
QULIPTA
  • AbbVie, Inc. $187
$187 25 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $160
$160 60 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

434 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record